Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
In a prospective randomized controlled trial, researchers evaluated the effectiveness of virtual reality as a nonpharmacologic therapy for pain in hospitalized patients with cancer.
In a population-based, cross-sectional study, researchers examined US women aged 20 to 49 years who were diagnosed with primary invasive breast cancer from 2000 through 2019.
In a long-term follow-up to SIERRA, a multicenter, randomized, controlled phase 3 study, researchers found that patients 55 years of age or older with active relapsed or refractory acute myeloid leukemia...
Although the immunotherapy plus chemotherapy did not improve disease-free survival (DFS) in newly diagnosed, high-risk patients with endometrial cancer, the combination therapy did improve DFS for patients...
Researchers who developed a meta-analysis of 19 randomized controlled trials found a statistically significant improvement in overall survival with sorafenib when compared with placebo for patients with...
